Past China Practices Come to Light As GSK Settles FCPA Probe
The US SEC has accepted a $20m payment from GSK to settle charges that it violated US legislation on foreign corrupt practices, in a decision that also throws further light on the UK-based firm's past sales inducement activities in China.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.